Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

16 Jul 2025

Abstract excerpt

Coronaviruses have caused three major endemics in the past two decades. Alarmingly, recent identification of novel zoonotic coronaviruses that caused human infections suggests the risk of future coronavirus outbreak caused by spillover infection from animal reservoirs remains high. Therefore, development of alternative therapeutic options with broad-spectrum anti-coronavirus activities are urgently needed. Here,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to PARP inhibition in cancer therapy
Share to SARS-CoV-2 and COVID-19 Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40670362
DOI: 10.1038/s41467-025-60832-z

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoPMID 40670362Read ↗

An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivoSemantic proximity Read ↗

Structure-based discovery of highly bioavailable, covalent, broad-spectrum coronavirus-M <sup>Pro</sup> inhibitors with potent in vivo efficacySemantic proximity Read ↗

Next-generation inhibitors of SARS-CoV-2 Mpro overcome the deficiencies of Paxlovid.Semantic proximity Read ↗

Single-dose treatment with a humanized neutralizing antibody affords full protection of a human transgenic mouse model from lethal Middle East respiratory syndrome (MERS)-coronavirus infectionSemantic proximity Read ↗

Cross-Protection Induced by Highly Conserved Human B, CD4 <sup>+,</sup> and CD8 <sup>+</sup> T Cell Epitopes-Based Coronavirus Vaccine Against Severe Infection, Disease, and Death Caused by Multiple SARS-CoV-2 Variants of ConcernSemantic proximity Read ↗

Pyronaridine Protects Against SARS-CoV-2 in MouseSemantic proximity Read ↗

Therapeutic efficacy of CT-P59 against P.1 variant of SARS-CoV-2Semantic proximity Read ↗

Efficacy of the oral nucleoside prodrug GS-5245 (Obeldesivir) against SARS-CoV-2 and coronaviruses with pandemic potentialSemantic proximity Read ↗

Identification of Broad Anti-Coronavirus Chemical Agents for Repurposing Against SARS-CoV-2 and Variants of ConcernSemantic proximity Read ↗

Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1Semantic proximity Read ↗

Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2Semantic proximity Read ↗

An Rna-Hydrolyzing Recombinant Minibody Simultaneously Inhibits the Propagation of Influenza a Virus and Coronavirus in in Vitro Co-Infection ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.